Ikonisys: Hospitex Expands in Ukraine through a Partnership with Diagen LLC to Fight Cancer
May 21 2024 - 12:10PM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories, today announces that Hospitex has signed a new
distribution partnership in Ukraine with Diagen LLC, a leading
Ukrainian distributor and laboratory services provider. This
collaboration aims at reinforcing the Company’s commitment to the
global fight against cancer.
Despite the challenging environment amidst the war, this
strategic alliance represents a significant step in Hospitex’s
mission to enhance the accessibility of advanced cancer diagnostic
tools and treatments and make innovative healthcare solutions
available to those who need them most. The market for cytology in
Ukraine is substantial with a growing emphasis on early cancer
detection and preventive healthcare. Urinary cytology is also
becoming more significant, with thousands of tests performed each
year to diagnose and monitor urinary tract cancers. By introducing
Hospitex's advanced diagnostic products into this market, the aim
is to significantly enhance the accuracy and efficiency of critical
tests.
In the framework of this partnership, Diagen LLC will both
distribute Hospitex's cutting-edge technologies and use them in its
own laboratory, particularly for Pap smear tests and urinary
cytology. Thanks to Hospitex’s expertise, Diagen LLC will enable
Ukrainian healthcare professionals to have access to reliable and
precise diagnostic tools.
“Partnering with Diagen LLC in Ukraine during such tumultuous
times is a testament to our dedication to the global fight against
cancer and its spread worldwide”, said Francesco Trisolini, CEO
of Hospitex. “We believe that every patient, regardless of
their circumstances, deserves the best possible care. This
initiative once again demonstrates our commitment to supporting
healthcare systems and providing crucial medical supplies where
they are most needed. Our new distributor and partner, Diagen LLC,
shares our vision and commitment to improving healthcare outcomes.
Together, we will focus on ensuring that even amidst adversity, the
fight against cancer continues unabated.”
The first delivery to Diagen LLC has recently been recorded
contributing to H1 2024 Hospitex’s revenue. The next phase of this
collaboration consists into introducing Ikonisys’ products into the
Ukrainian market, further enhancing diagnostic capabilities and
patient care.
Mario Crovetto, CEO of Ikonisys, declares: “We are
thrilled to announce this new milestone as our ambition to
contribute to the fight against cancer globally is very high. We
look forward to providing active support to this territory in the
midst of conflict and improve the lives of the population in need
there.”
This collaboration is part of Hospitex’s and Ikonisys’ broader
strategy to expand their global footprint and provide essential
medical technology to underserved regions. By enhancing their
distribution network, the Companies are taking proactive steps to
address the global burden of cancer, delivering hope and improved
health outcomes to communities in need.
About Hospitex International Hospitex International is
the world leading company for cytology standardized monolayer
preparations. With CYTOfast it has re-invented the cytological
diagnostics. Hospitex offers a full range of integrated solutions
aimed at streamlining diagnostic processes in cytology. The global
shortage of expertise in pathology requires tools and technologies
that enable diagnostic safety, efficiency and capacity building. In
this area, Hospitex is recognized as the precision diagnostics
player in cytology.
For more information: https://www.hospitex.com/en/
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to
www.ikonisys-finance.com
Disclaimer This press release contains forward-looking
statements about the Company's prospects and development. These
statements are sometimes identified by the use of the future tense,
the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should",
"could", "would" or "will" or, where appropriate, the negative of
these terms or any other similar variants or expressions. This
information is not historical data and should not be construed as a
guarantee that the facts and data set forth will occur. This
information is based on data, assumptions and estimates considered
reasonable by the Company. It is subject to change or modification
due to uncertainties relating to the economic, financial,
competitive and regulatory environment. This information contains
data relating to the Company's intentions, estimates and objectives
concerning, in particular, the market, strategy, growth, results,
financial situation and cash flow of the Company. The
forward-looking information contained in this press release is made
only as of the date of this press release. The Company does not
undertake to update any forward-looking information contained in
this press release, except as required by applicable law or
regulation. The Company operates in a competitive and rapidly
changing environment and therefore cannot anticipate all of the
risks, uncertainties or other factors that may affect its business,
their potential impact on its business or the extent to which the
materialization of any one risk or combination of risks could cause
results to differ materially from those expressed in any
forward-looking information, it being recalled that none of this
forward-looking information constitutes a guarantee of actual
results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521453082/en/
Hospitex International Marco Testini Investor Relations
marco.testini@hospitex.com
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
From May 2024 to Jun 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
From Jun 2023 to Jun 2024